The objectives of this research are to devise improved non-viral gene carriers and to apply them in a Gene-Directed Enzyme Prodrug Therapy (GDEPT) protocol in a rat brain human tumor model. The question we will address is: will an optimized non-viral GDEPT protocol expressing yeast cytosine deaminase provide better therapy then a targeted liposome chemotherapy protocol in brain tumors? The hypothesis guiding this plan is that a combination of multiple levels of targeting will result in robust tumor-specific cytosine deaminase gene expression and improved tumor therapy. The four levels of targeting employed in these plans are: convective enhanced diffusion (CED) into the brain tumor, bioresponsive liposome gene formulations, CD44 receptor targeting, and a tumor matrix targeted enzyme. Tumor-localized cytosine deaminase will then convert the systemically administered prodrug, fluorocytosine (FC), to fluorouracil (FU), the active agent. This particular combination of approaches will enhance access of the carrier to the tumor, improve percolation of the carrier through the tumor, increase carrier attachment to tumor cells and improve intracellular delivery of the plasmid and bystander activity of the therapeutic gene. There are four major activities in the program: (1) synthesis of novel components and assembly of the components with plasmid DNA into a small diameter, stable liposome designated a nanolipoparticle (NLP)(2) characterization of the factors that control the performance of the NLP in cells (pH sensitivity, cell association, gene transfer activity, toxicity) and in animals (distribution, pharmacokinetics, toxicity and gene expression) after CED into the brain. (3) Construction of an extracellular matrix targeted cytosine deaminase to improve the bystander effect. (4) Comparison of the therapeutic effect of the optimized GDEPT to the effect of fluoroorotic acid delivered in a CD44 targeted liposome of similar physicochemical characteristics as the NLP. Fluorocytosine and fluoroorotic acid both exert their therapeutic effect through FU. The concentration of FU and metabolites will be measured in the tumor and plasma. We will determine which approach provides a greater drug concentration x time profile in the tumor as opposed to non-target cells. The combination of synthetic chemistry, molecular biology, pharmaceutics, and pharmacology will permit us to determine if a non-viral GDEPT is superior to a targeted prodrug for the treatment of brain tumors when both protocols are given by CED. These results will provide a rationale for targeted therapies for human brain tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA107268-02
Application #
6861041
Study Section
Pharmacology A Study Section (PHRA)
Program Officer
Song, Min-Kyung H
Project Start
2004-03-01
Project End
2009-02-28
Budget Start
2005-03-01
Budget End
2006-02-28
Support Year
2
Fiscal Year
2005
Total Cost
$365,362
Indirect Cost
Name
University of California San Francisco
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Motion, J P Michael; Huynh, Grace H; Szoka Jr, Francis C et al. (2011) Convection and retro-convection enhanced delivery: some theoretical considerations related to drug targeting. Pharm Res 28:472-9
Hashizume, Rintaro; Ozawa, Tomoko; Dinca, Eduard B et al. (2010) A human brainstem glioma xenograft model enabled for bioluminescence imaging. J Neurooncol 96:151-9
Huang, Zhaohua; Hwang, Peter; Watson, Douglas S et al. (2009) Tris-nitrilotriacetic acids of subnanomolar affinity toward hexahistidine tagged molecules. Bioconjug Chem 20:1667-72
Platt, Virginia M; Szoka Jr, Francis C (2008) Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 5:474-86
Hashizume, Rintaro; Ozawa, Tomoko; Gryaznov, Sergei M et al. (2008) New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol 10:112-20
MacKay, J Andrew; Li, Weijun; Huang, Zhaohua et al. (2008) HIV TAT peptide modifies the distribution of DNA nanolipoparticles following convection-enhanced delivery. Mol Ther 16:893-900
Huynh, Grace H; Ozawa, Tomoko; Deen, Dennis F et al. (2007) Retro-convection enhanced delivery to increase blood to brain transfer of macromolecules. Brain Res 1128:181-90
Huynh, Grace H; Deen, Dennis F; Szoka Jr, Francis C (2006) Barriers to carrier mediated drug and gene delivery to brain tumors. J Control Release 110:236-59
MacKay, J Andrew; Deen, Dennis F; Szoka Jr, Francis C (2005) Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res 1035:139-53